Brief: Sellas Life Sciences’ Cdk9 Inhibitor Gfh009 Demonstrates Tumor Growth Inhibition In Small Cell Lung Cancer Murine Model
01/12/2022 13:33
Dec 1 (Reuters) - Sellas Life Sciences Group Inc
SLS.O :
* SELLAS LIFE SCIENCES’ CDK9 INHIBITOR GFH009 DEMONSTRATES
TUMOR
GROWTH INHIBITION IN SMALL CELL LUNG CANCER MURINE MODEL
* SELLAS LIFE SCIENCES - GFH009 EXHIBITS ROBUST ACTIVITY
AGAINST
SMALL CELL LUNG CANCER XENOGRAFTS, AS MONOTHERAPY & WITH PARP
INHIBITOR OLAPARIB
* SELLAS LIFE SCIENCES GROUP - RESULTS SUPPORT DESIGNATING
SMALL
CELL LUNG CANCER AS FIRST INDICATION IN PLANNED SOLID CANCER
BASKET TRIAL FOR GFH009
Source text for Eikon: ID:nGNX4lgwmW
Further company coverage: SLS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sellas Life Sciences
See all newsBrief: Sellas Life Sciences Reaches 80Th Event In Phase 3 Regal Trial Of Galinpepimut-S (Gps) In Acute Myeloid Leukemia
SELLAS Life Sciences Q2 net loss widens on higher expenses
Brief: SELLAS Life Sciences Q2 Net Income USD -9.605 Million
Arbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
SELLAS Life Sciences Q1 net loss widens on higher expenses